VeriSilicon Partners With LVGL to Enable Advanced GPU Acceleration for Wearable Devices and Beyond
29.11.2024 01:00:00 CET | Business Wire | Press release
LVGL adds VeriSilicon’s 3D and VGLite 2.5D GPUs support to its library for a wide range of embedded applications
VeriSilicon (688521.SH) today announced a strategic partnership with LVGL, the leading open-source graphics library for embedded systems, to support VeriSilicon’s low-power 3D and VGLite 2.5D GPU technology within the LVGL library. This partnership aims to optimize performance and expand graphic processing capabilities for a wide range of embedded applications. As one of the first providers of 3D GPU technology for the LVGL ecosystem, VeriSilicon will contribute to advancing 3D rendering capabilities within the LVGL library.
LVGL is the most popular free and open-source embedded graphics library to create beautiful User Interfaces (UIs) for any Microcontroller Units (MCUs), Micro Processor Units (MPUs), or display type. By integrating VeriSilicon’s low-power and high-performance GPU solutions into LVGL’s graphics ecosystem, it offers developers the ability to rapidly deliver improved visual experiences, while maintaining power efficiency on compact, resource-constrained devices.
Actions Technology, a low-power AIoT fabless semiconductor company, is among the first to adopt this integrated solution in their smart watch System-on-Chips (SoCs). The company recognizes the potential of VeriSilicon’s low-power GPU technology, which, in conjunction with LVGL’s graphics library, will enhance the user experience of next-generation wearable devices.
Gabor Kiss-Vamosi, CEO of LVGL, said, “VeriSilicon’s VGLite 2.5D GPU technology has pioneered a new era in the embedded world, enabling complex vector graphics with exceptional speed and low power consumption. Now, we stand at the edge of a new revolution: the arrival of 3D GPUs to MCUs. This breakthrough will transform the embedded UI landscape, unlocking never-before-seen possibilities for user interfaces on small, resource-constrained, and battery-powered devices. At LVGL, we are excited to embrace this technology and harness its potential across a wide range of platforms. Our goal is to provide a great developer experience for VeriSilicon’s 3D GPUs, enabling seamless integration of 2D, 2.5D, and 3D content that will no doubt lead to some remarkable embedded applications.”
Tim Zhang, Wearable and Sensing Business Unit General Manager of Actions Technology, said, “LVGL’s flexible and powerful graphics solutions are essential to enhance the user interfaces of our wearable products. As the wearable industry embraces 3D graphics, the adoption of VeriSilicon’s powerful and energy-efficient technologies enables us to push the boundaries of innovation, delivering rich 3D graphics with low power consumption.”
“Wearable products are experiencing rapid growth, offering extended functionalities that go far beyond traditional watches. They have evolved into accessible information devices with integrated health monitoring features,” said Weijin Dai, Executive Vice President and General Manager of VeriSilicon’s IP Division. “With this growth, delivering a powerful user interface to effectively communicate information on small displays, while maintaining low power consumption, has become essential. At VeriSilicon, we work closely with our customers to integrate 3D GPU technology into their next-generation products. As a leading provider of wearable GPUs for both 2.5D and 3D applications, we collaborate with LVGL and partners like Actions to drive innovation and achieve this mission.”
About LVGL
LVGL Kft. is the creator of LVGL, the leading free and open-source graphics library for embedded systems, enabling high-quality UIs on any Microcontroller Unit (MCU), Micro Processor Unit (MPU), or display type. With a global community and industry partnerships, LVGL empowers developers to build visually rich, responsive, and efficient UIs for resource-constrained devices from wearables to industrial equipment. For more information, visit www.lvgl.io.
About Actions Technology
Actions Technology (688049.SH) is a leading low-power AIoT fabless semiconductor company in China. We excel in providing high-quality and low-latency wireless audio experiences while prioritizing power efficiency. Our core expertise includes high-performance audio ADC/DAC, voice pre-processing, audio encoding/decoding, and audio post-processing technologies, enabling a superior audio signal chain. Additionally, we specialize in low-latency wireless connectivity with Bluetooth RF, baseband, and protocol stack technologies at the core. For more information about Actions® high-quality, low-latency platform, visit www.actionstech.com.
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241128646659/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom